返回 
加入收藏
头孢他啶阿维巴坦单药对比联合疗法用于碳青霉烯类耐药革兰氏阴性菌感染的疗效及影响因素
x
请在关注微信后，向客服人员索取文件
| 篇名： | 头孢他啶阿维巴坦单药对比联合疗法用于碳青霉烯类耐药革兰氏阴性菌感染的疗效及影响因素 |
| TITLE： | Clinical efficacy and influencing factors of ceftazidime and avibactam monotherapy versus combination therapy in the treatment of CRGNB infection |
| 摘要： | 目的 比较头孢他啶阿维巴坦（CZA）单药与联合疗法用于碳青霉烯类耐药革兰氏阴性菌（CRGNB）感染的疗效，并分析其影响因素。方法回顾性收集2020年1月至2025年3月在我院接受CZA治疗的CRGNB感染的患者资料，按用药的不同分为CZA单药组（52例）与CZA联合组（85例）。比较两组患者的疗效，记录分离菌株的药敏试验结果；采用多因素Logistic回归模型分析影响CRGNB感染患者临床疗效的因素。结果CZA联合组患者的细菌清除率显著高于CRZ单药组（P＝0.012），但两组患者的30d病死率及临床有效率比较，差异均无统计学意义（P＞0.05）。耐碳青霉烯类肺炎克雷伯菌对替加环素敏感率最高（87.3%），耐碳青霉烯类铜绿假单胞菌对阿米卡星的敏感率为90.9%；5株分离菌株对CZA耐药。多因素Logistic回归分析结果显示，发生肺部感染、接受连续性肾脏替代治疗（CRRT）、疗程不足与临床治疗失败显著相关（P＜0.05）。结论CZA联合疗法与单药治疗CRGNB感染的临床有效率相当，但联合疗法的细菌清除率更高。发生肺部感染、接受CRRT以及疗程不足是临床治疗失败的独立危险因素。 |
| ABSTRACT： | OBJECTIVE To compare the efficacy of ceftazidime and avibactam （CZA） monotherapy and combination therapy in the treatment of carbapenem-resistant Gram-negative bacteria （CRGNB） infections， and analyze the influencing factors. METHODS The data of patients with CRGNB infection who received CZA treatment from January 2020 to March 2025 were collected retrospectively. The patients were divided into the CZA monotherapy group （52 cases） and the CZA combination therapy group （85 cases） according to treatment regimen. The therapeutic effects of the two groups were compared， and the drug susceptibility results of isolated strains were recorded. The multivariate Logistic regression model was used to analyze the factors influencing clinical efficacy of CRGNB patients. RESULTS The bacterial clearance rate of patients was significantly higher in the CZA combination therapy group than in the CZA monotherapy group （P＝0.012）. However， when comparing the 30-day mortality rate and the clinical response rate between the two groups， no statistically significant differences were observed （P＞0.05）. Among the isolates， carbapenem-resistant Klebsiella pneumoniae had the highest sensitivity to tigecycline （87.3%） and carbapenem-resistant Pseudomonas aeruginosa showed 90.9% sensitivity to amikacin. Five isolates were resistant to CZA. The multivariate Logistic regression showed， lung infection， receiving continuous renal replacement therapy （CRRT）， and inadequate treatment courses were significantly correlated with clinical treatment failure （P＜0.05）. CONCLUSIONS For CRGNB infection， the clinical efficacy of CZA combination therapy is similar to that of monotherapy， but the combination therapy has a higher bacterial clearance rate. Lung infections， receiving CRRT and inadequate treatment courses （No. are independent risk factors for clinical treatment failure. |
| 期刊： | 2025年第36卷第16期 |
| 作者： | 刘昌伟；王小华；张慧；王冉冉；肖荣城；方玲 |
| AUTHORS： | LIU Changwei，WANG Xiaohua，ZHANG Hui，WANG Ranran，XIAO Rongcheng，FANG Ling |
| 关键字： | 头孢他啶阿维巴坦；单药疗法；联合疗法；碳青霉烯类耐药革兰氏阴性菌；疗效；影响因素 |
| KEYWORDS： | ceftazidime and avibactam； monotherapy； |
| 阅读数： | 7 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
